AI-guided selection
Computational screening narrows complex biology into candidate epitopes designed for diagnostic performance.
Diagnostics everywhere
UbiqueBio
AI-designed synthetic reagents for precise, affordable and scalable diagnostic tests.
Founded
2022
Formats
ELISA and rapid tests
Footprint
USA, Mexico, Argentina
Backed by
GridX
Platform
From target discovery to diagnostic-ready reagents.
UbiqueBio combines immunoinformatics, peptide engineering and assay development to create synthetic reagents with high specificity and practical manufacturability.
Synthetic reagents
Animal-free reagent design supports reproducibility, scale and rapid iteration across disease targets.
Assay integration
Candidates move into ELISA and lateral flow workflows for partners building deployable diagnostics.
Solutions
Built for teams that need better tests, faster.
Test developers
License or co-develop differentiated reagents to improve specificity, speed up validation and reduce development risk.
Health companies
Expand diagnostic portfolios with synthetic antigen and antibody strategies across infectious disease and screening use cases.
Governments and NGOs
Deploy affordable screening programs where logistics, cost and access determine real-world impact.
Why it matters
Precision diagnostics should not be limited by geography or infrastructure.
Antigen and antibody tests can scale into settings where molecular diagnostics are too costly or operationally complex. UbiqueBio's platform is designed to make that access more reliable.
High specificity
Designed to separate signal from biological noise.
Scalable formats
Compatible with lab-based and point-of-care workflows.
Animal-free path
Synthetic reagents reduce dependency on variable biological production.
Company
A biotech team focused on accessible diagnostics.
Founded in 2022, UbiqueBio brings together biotechnology, immunoassay development, data science and business development across the Americas.
Follow on LinkedInInvestors
Private data room ready for gated access.
The public site stays static. Investor materials can live under a protected subdomain with identity-based access, auditability and no shared password.
Contact
Partnerships, licensing and diagnostic development.
For product, partnership, customer or investor inquiries, contact the UbiqueBio team.